Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven A Grover

Showing results (1-10 of 35) with videos related to

Pageof 4
Sort By:
The Canadian Journal of Cardiology|February 25, 2006
PROVE-IT proves that lower is better: a contrary viewSteven A Grover
The Canadian Journal of Urology|June 1, 1997
Economics of prostate cancer: a computer modelSteven A. Grover
Expert Review of Pharmacoeconomics & Outcomes Research|October 8, 2009
Costs of dyslipidemiaHanna Zowall, Steven A Grover
The Canadian Journal of Cardiology|June 21, 2011
The challenges and benefits of cardiovascular risk assessment in clinical practiceSteven A Grover, Ilka Lowensteyn
Epidemiology (Cambridge, Mass.)|July 16, 2003
Improving the prediction of cardiovascular risk: interaction between LDL and HDL cholesterolSteven A Grover, Marc Dorais, Louis Coupal
Hypertension (Dallas, Tex. : 1979)|November 17, 2004
Treating osteoarthritis with cyclooxygenase-2-specific inhibitors: what are the benefits of avoiding blood pressure destabilization?Steven A Grover, Louis Coupal, Hanna Zowall
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|December 14, 2007
Estimating the cost effectiveness of ramipril used for specific clinical indications: comparing the outcomes in four clinical trials with a common economic modelSteven A Grover, Louis Coupal, Ilka Lowensteyn
The Canadian Journal of Cardiology|April 11, 2008
Determining the cost-effectiveness of preventing cardiovascular disease: are estimates calculated over the duration of a clinical trial adequate?Steven A Grover, Louis Coupal, Ilka Lowensteyn
CMAJ Open|April 7, 2018
Evaluation of the cost-effectiveness of evolocumab in the FOURIER study: a Canadian analysisTodd C Lee, Mohammed Kaouache, Steven A Grover
The American Journal of Cardiology|February 22, 2005
Impact of dyslipidemia associated with Highly Active Antiretroviral Therapy (HAART) on cardiovascular risk and life expectancySteven A Grover, Louis Coupal, Norbert Gilmore, et al.
Pageof 4

Showing results (1-10 of 35) with videos related to

Sort By:
Pageof 4
The Canadian Journal of Cardiology|February 25, 2006
PROVE-IT proves that lower is better: a contrary viewSteven A Grover
The Canadian Journal of Urology|June 1, 1997
Economics of prostate cancer: a computer modelSteven A. Grover
Expert Review of Pharmacoeconomics & Outcomes Research|October 8, 2009
Costs of dyslipidemiaHanna Zowall, Steven A Grover
The Canadian Journal of Cardiology|June 21, 2011
The challenges and benefits of cardiovascular risk assessment in clinical practiceSteven A Grover, Ilka Lowensteyn
Epidemiology (Cambridge, Mass.)|July 16, 2003
Improving the prediction of cardiovascular risk: interaction between LDL and HDL cholesterolSteven A Grover, Marc Dorais, Louis Coupal
Hypertension (Dallas, Tex. : 1979)|November 17, 2004
Treating osteoarthritis with cyclooxygenase-2-specific inhibitors: what are the benefits of avoiding blood pressure destabilization?Steven A Grover, Louis Coupal, Hanna Zowall
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|December 14, 2007
Estimating the cost effectiveness of ramipril used for specific clinical indications: comparing the outcomes in four clinical trials with a common economic modelSteven A Grover, Louis Coupal, Ilka Lowensteyn
The Canadian Journal of Cardiology|April 11, 2008
Determining the cost-effectiveness of preventing cardiovascular disease: are estimates calculated over the duration of a clinical trial adequate?Steven A Grover, Louis Coupal, Ilka Lowensteyn
CMAJ Open|April 7, 2018
Evaluation of the cost-effectiveness of evolocumab in the FOURIER study: a Canadian analysisTodd C Lee, Mohammed Kaouache, Steven A Grover
The American Journal of Cardiology|February 22, 2005
Impact of dyslipidemia associated with Highly Active Antiretroviral Therapy (HAART) on cardiovascular risk and life expectancySteven A Grover, Louis Coupal, Norbert Gilmore, et al.
Pageof 4